PRA was founded as the Anti-Inflammatory Drug Study Group in 1976, renamed PRA in 1982, as it expanded into other therapeutic areas besides inflammation. In 2013 the company was acquired by
Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019. In August 2017, the company acquired
Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million. PRA's 2018 revenue was US$2.87 billion. PRA was acquired by
ICON PLC on 1 July 2021. == References ==